Related Experiment Video
Updated: Aug 6, 2026

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
Published on: February 28, 2025
Stereoselective Covalent Targeting of BTK(C481S) and Kinases with β-Lactone Electrophiles
Celine D Wang1,2, Polina E Barzova1, Julian Robles1
1Department of Chemistry, University of California, Berkeley, California 94720, USA.
Abstract:
The cysteine to serine mutation at residue 481 of Bruton's tyrosine kinase (BTK) is the most common mechanism of clinical resistance against ibrutinib for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. We report small molecule ligands containing chiral β-lactone electrophiles to address this challenge. The asymmetric warhead enabled stereoselective covalent modification of wild-type and ibrutinib-resistant mutant BTK(C481S) through distinct sites of reactivity. Building on these findings, we developed kinase-directed β-lactone probes and demonstrated that individual enantiomers preferentially engage distinct subsets of the kinome. These studies establish β-lactones as stereochemically encodable covalent warheads whose stereochemistry can serve as a selectivity filter in covalent drug discovery.
Insights
Researchers developed novel chiral β-lactone molecules to overcome resistance to ibrutinib, a drug used for certain leukemias and lymphomas. These molecules selectively target Bruton
Area of Science:
- Medicinal Chemistry
- Chemical Biology
- Oncology
Background:
- Bruton's tyrosine kinase (BTK) is a key target in treating B-cell malignancies.
- Cysteine 481 (C481) mutations in BTK confer clinical resistance to ibrutinib.
- Developing strategies to overcome ibrutinib resistance is crucial for effective cancer therapy.
Purpose of the Study:
- To design and synthesize novel small molecule ligands targeting resistant BTK mutations.
- To explore the potential of chiral β-lactone electrophiles as covalent warheads for selective kinase inhibition.
- To investigate the stereochemical control of covalent modification for drug discovery.
Main Methods:
- Synthesis of chiral β-lactone electrophiles.
- Biochemical assays to assess covalent modification of wild-type and mutant BTK.
- Development of kinase-directed probes for kinome profiling.
- Stereoselective synthesis and evaluation of individual enantiomers.
Main Results:
- Chiral β-lactones achieved stereoselective covalent modification of both wild-type and BTK(C481S) mutant.
- Distinct sites of reactivity were observed for different enantiomers.
- Kinase-directed probes revealed enantiomer-specific engagement of kinome subsets.
- β-lactones function as stereochemically encodable covalent warheads.
Conclusions:
- Chiral β-lactones represent a promising strategy to overcome ibrutinib resistance in BTK-related cancers.
- The stereochemistry of β-lactones can be utilized as a selectivity filter in covalent drug design.
- This work expands the toolbox for developing targeted covalent inhibitors with improved selectivity and efficacy.
Related Concept Videos
α-Alkylation of Ketones via Enolate Ions
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Regioselectivity and Stereochemistry of Hydroboration
Hydroboration proceeds in a concerted fashion with the attack of borane on the π bond, giving a cyclic four-centered transition state. The –BH2 group is bonded to the less substituted carbon and –H to the more substituted carbon. The concerted nature requires the simultaneous addition of –H and –BH2 across the same face of the alkene giving syn stereochemistry.
SN2 Reaction: Stereochemistry
If the substrate is an achiral molecule at the α-carbon, the inversion of configuration is not observed.
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Alkylation of β-Ketoester Enolates: Acetoacetic Ester Synthesis

